Dr. Rachelle Landgraf
Bioanalytical Professional: Advancing science through analytical method development
Experienced Director with a demonstrated history of working in the pharmaceuticals industry. Skilled in Method Development, Liquid Chromatography-Mass Spectrometry (LC-MS), Protein Chemistry, MALDI-TOF, and High-Performance Liquid Chromatography (HPLC). Strong professional with a PhD focused in Analtyical Chemistry from University of Florida.
Oct 2020 - Present
LC-MS/MS method development for the detection of pesticides in cannabis.
Dec 2018 - Present
Marine Ventures International, Inc.
Method development for CSA Ocean Sciences for the detection of total petroleum hydrocarbons in sea water using solid phase extraction with fluorescence detection
Feb 2014 - Jul 2017
Wildcat Pharmaceutical Development Center
Mass Spectrometry Director
Project implementation and management for pre-clinical and phase I analytical method development Pharmacokinetic studies for Onyx Pharmaceuticals to determine carfilzomib (MW 719.2 Da) concentrations of a liposomal formulation in mouse tissue by means of SPS extraction and LC-MS/MS detection Pharmacokinetic studies for The University of Texas MD Anderson Cancer Center to determine WP1066 (MW 356.2 Da) concentrations in mouse tissue by means of liquid-liquid extraction and LC-MS/MS detection Feasibility study for The University of MD Anderson Cancer Center for the detection of novel monosaccharides by LC-MS/MS Feasibility study for Mallinckrodt Pharmaceuticals for the detection of hormones in mouse serum by LC-MS/MS Feasibility study for Davos Pharmaceuticals for the detection of heavy and light chains and active pharmaceutical ingredient of the antibody Kadcyla ado-trastuzumab emtansine (MW 148.5 kDa) using bottom-up LC-MS/MS
Aug 2011 - Dec 2013
MD Anderson Cancer Center
Lead scientist for pre-clinical and phase I analytical method development and biomarker discovery Pharmacokinetic studies for clinicians using a range of anti-cancer agents in various tissues including 5-azacytidine (MW 244.2 Da), doxorubicin (MW 543.5 Da), nadolol (MW 309.4 Da), histamine (MW 111.2 Da), serotonin (MW 176.2 Da) and adenosine (MW 267.2 Da) by means of liquid-liquid extraction and normal, reverse and HILIC LC-MS/MS
Jul 2009 - Aug 2011
Scripps Research Institute
Collaborating scientist for developing hydrogen/deuterium exchange (HDX) technology Probing the mechanism of action of AMP kinase (MW 134-150 kDa ) in collaboration with Pfizer using bottom-up LC-MS/MS Probing the mechanism of action of androgen (MW 110 kDa), estrogen (MW 66 kDa) and progesterone (MW 90 kDa) receptors in collaboration with Baylor College of Medicine using bottom-up LC-MS/MS
2004 - 2009
University of Florida
1999 - 2004
Texas A&M University-Corpus Christi